Shares of leading pet healthcare diagnostics provider Idexx Laboratories (NASDAQ: IDXX) were up by 9% this week as of 4 p.m. ET Thursday, according to data provided by S&P Global Market Intelligence.
Idexx Labs reported fourth-quarter earnings Monday morning that surpassed analysts' expectations for revenue and earnings per share (EPS).
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks »
A strong Q4 and even better guidance for 2025
Idexx delivered revenue and EPS growth of 6% and 13% in Q4, but its guidance appears to have caught the market's attention. Looking ahead to 2025, management expects the company to grow sales by 4% to 7%, while EPS is projected to jump between 10% and 15%.
While these may not seem like incredible results, this growth is exceptional, considering that veterinary visits per practice have declined for 12 consecutive quarters. After pulling forward growth during the pandemic, the veterinary industry has yet to return to normal, making Idexx's Q4 results and guidance reassuring for investors.
The next chapter of Idexx's growth story?
Idexx operates using a razor-and-blades business model. It installs diagnostic instruments at veterinary clinics and then generates recurring revenue from the equipment.
Once these instruments are in place, the company collects recurring revenue from consumables, reference lab diagnostic assistance, and consulting services. These recurring sales equal 79% of Idexx's total revenue and give the company very steady financials from year to year.
The company will launch its newest "razor" -- the Idexx inVue Dx cellular analyzer -- in March this year, potentially starting a new wave of growth. This new instrument can detect canine lymphoma early and could expand to most cancer types within three years, according to management.
Trading at 43 times earnings, Idexx trades at a premium valuation, but I believe it remains a once-in-a-decade opportunity, even after rising this week.
Should you invest $1,000 in Idexx Laboratories right now?
Before you buy stock in Idexx Laboratories, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Idexx Laboratories wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $788,619!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of February 3, 2025
Josh Kohn-Lindquist has positions in Idexx Laboratories. The Motley Fool recommends Idexx Laboratories. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
